Evaluation of latent membrane protein 1 and microRNA‑155 for the prognostic prediction of diffuse large B cell lymphoma
Open Access
- 24 April 2018
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 15 (6) , 9725-9734
Abstract
Diffuse large B cell lymphoma (DLBCL) has previously been demonstrated to contribute to the mortality of lymphoma with various aggressive features. The prognostic role of the biomarkers latent membrane protein (LMP) 1 and microRNA‑(miR)‑155 in DLBCL remain controversial. The present study primarily aimed to assess the effect of LMP1 and miR‑155 on the survival of DLBCL patients, and additionally evaluate the clinical features to observe their influence on outcomes, compared with previous studies. Formalin‑fixed and paraffin‑embedded samples were collected from our center between May 2010 and December 2011. Microarray analysis, immunohistochemical analysis and reverse transcription-quantitative polymerase chain reaction were used to evaluate the expression of LMP1 and miR‑155. The association between biomarkers or clinical features and patient outcomes was assessed using the log‑rank statistical test, Cox proportional hazard model and Kaplan‑Meier method. SPSS software was used to statistically analyze the data. A total of 82 patients were included in the present study. The results demonstrated that high expression of LMP1 and miR‑155 may be associated with a poor progression‑free survival rate, while a high International Prognostic Index score and high expression of LMP1 may be associated with a poor overall survival rate. These results indicated that LMP1 and miR‑155 may be novel and reliable biomarkers for the prognostic prediction of lymphoma, and will potentially be analyzed in the future to evaluate patient prognosis.Keywords
This publication has 36 references indexed in Scilit:
- The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximabAnnals of Hematology, 2014
- Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B‐cell non‐Hodgkin lymphomaBritish Journal of Haematology, 2014
- Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane ProteinsJournal of Clinical Oncology, 2014
- Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin LymphomaClinical Cancer Research, 2014
- The microRNA miR-155 controls CD8+ T cell responses by regulating interferon signalingNature Immunology, 2013
- MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphomaLaboratory Investigation, 2013
- LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL)Diagnostic Pathology, 2012
- Genetic Diversity of EBV-Encoded LMP1 in the Swiss HIV Cohort Study and Implication for NF-Κb ActivationPLOS ONE, 2012
- Accumulation of miR-155 and BIC RNA in human B cell lymphomasProceedings of the National Academy of Sciences of the United States of America, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001